Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OBI-3424 in Relapsed/Refractory T-ALL/T-LBL
NCT04315324Phase 2Active, not recruiting
- Sponsor
- SWOG Cancer Research Network
- Start
- Feb 2021
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of odafosfamide in t-cell acute lymphoblastic leukemia (T-ALL), T cell lymphoblastic lymphoma (T-LBL), sponsored by SWOG Cancer Research Network. Started Feb 2021; status: active, not recruiting.
02
Drugs
odafosfamide
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT04315324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04315324.